Adaptimmune Therapeutics Plc Price/Book
What is the Price/Book of Adaptimmune Therapeutics Plc?
The Price/Book of Adaptimmune Therapeutics Plc is 5.72
What is the definition of Price/Book?
Price to book ratio represents the ratio between a company’s stock value and the book value per share.
mrq (most recent quarter)
The price to book ratio, or P/B ratio, is a financial ratio used to compare a company's current market price to its book value. It is also sometimes known as a market to book ratio or price to equity ratio. The calculation of a price to book ratio can be performed in two ways. It can be calculated as the company's market capitalization divided by the company's total book value from its balance sheet. It can also be calculated using per-share values and dividing a company's current share price by the book value per share (i.e. its book value divided by the number of outstanding shares).
The P/B ratio varies between industries. The industries that require more infrastructure capital (for each dollar of profit) will usually trade at P/B ratios much lower than, for example, consulting firms. P/B ratios are commonly used to compare banks, because most assets and liabilities of banks are constantly valued at market values. A higher P/B ratio implies that investors expect management to create more value from a given set of assets, all else equal (and/or that the market value of the firm's assets is significantly higher than their accounting value).
P/B ratios do not, however, directly provide any information on the ability of the firm to generate profits or cash for shareholders. This ratio also gives some idea of whether an investor is paying too much for what would be left if the company went bankrupt immediately. For companies in distress, the book value is usually calculated without the intangible assets that would have no resale value. In such cases, P/B should also be calculated on a "diluted" basis, because stock options may well vest on sale of the company or change of control or firing of management.
Price/Book of companies in the Health Care sector on NASDAQ compared to Adaptimmune Therapeutics Plc
What does Adaptimmune Therapeutics Plc do?
adaptimmune llc is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary t-cell receptor platform that has the potential to transform the treatment of cancer. established in 2008, the company has grown from being privately held to one of the most successful biopharmaceutical initial public offerings (ipo) in 2015. with u.s. operations based in philadelphia, pa, adaptimmune is a company founded on strong science that has led to a robust pipeline of immuno-oncology product candidates, a growing research & development platform and ongoing plans for expansion. for more information about adaptimmune, please visit www.adaptimmune.com. if interested in joining our fast growing team, click on the careers tab of this page.
Companies with price/book similar to Adaptimmune Therapeutics Plc
- Miragen Therapeutics Inc has Price/Book of 5.71
- Aeeris has Price/Book of 5.71
- AusNet Services Ltd has Price/Book of 5.71
- Teradyne has Price/Book of 5.71
- NIO Inc has Price/Book of 5.71
- Solid Biosciences Inc has Price/Book of 5.72
- Adaptimmune Therapeutics Plc has Price/Book of 5.72
- STADA Arzneimittel Aktiengesellschaft has Price/Book of 5.72
- Amlogic (Shanghai) Co has Price/Book of 5.72
- La Forestiere Equatoriale SA has Price/Book of 5.72
- Palred Technologies has Price/Book of 5.72
- The Hi-Tech Gears has Price/Book of 5.73
- Renren Inc has Price/Book of 5.73